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Relapse risk was significantly lower in the TBF when compared with BuCy group (HR 0.6, P = 
.02), while NRM did not differ. No significant difference was observed in LFS and OS 
aGVHD (HR 1.8, P = .06) and inferior cGVHD (HR 0.7, P = .04) when compared with BuCy. In 
more evident (HR 0.4, P = .02), leading to a trend for 
better LFS in favor of TBF (HR 0.7, P = .10), while OS did not differ between the two cohorts. In conclusion, TBF represents a valid 






1 | INTRODUCTION  
 
The concept of conditioning regimen for allo-SCT has been recently 
reshaped. Historical protocols relied mostly on total body irradiation 
(TBI), and the combination of cyclophosphamide (Cy) and TBI had 
been widely used as preparatory regimen for allo-SCT in acute mye- 
loid leukemia (AML) for decades.
1
 The introduction of alkylators in 
substitution of TBI moved the field forward. The combination of 
busulfan and cyclophosphamide (BuCy) was developed in the late 
1980s,
2,3
 and since then has remained a standard of care for young, 
fit patients with AML undergoing allo-SCT. In the last two decades a 
significant effort has been made to minimize regimen toxicity, leading 
to the possibility of extending the availability of allo-SCT to elderly 
and unfit patients.
4,5
 This tendency resulted in the development of a 
plethora of nonmyeloablative (NMA), reduced intensity (RIC) and so- 
called “reduced toxicity” regimens, in ascending order according to the 
intensity of myeloablation.
6,7
 Nevertheless, recent evidence tempered 
enthusiasm about the mitigation of conditioning intensity unless nec- 
essary (ie, for older and/or frail patients with high comorbidities 
[HCT-CI] score).
8,9
 In fact, standard myeloablative protocols remain 
today the primary option in young, fit patients with AML, as dose 
intensity is warranted to control residual disease at transplant while 
waiting for the graft-vs.-leukemia effect to take over. This concept 
prompt investigators to develop novel conditioning protocols which 
could combine an effective anti leukemic activity with an acceptable 
toxicity profile. 
Thiotepa is an alkylating compound which has been included in 
many preparative regimens for transplant as it holds a good anti 
tumoral effect in combination with immunosuppressive properties 
and limited nonhematologic toxicity.
10–12
 The combination of thio- 
tepa, busulfan, and fludarabine (TBF) was initially proposed as condi- 
tioning regimen for cord blood transplant;
13,14
 subsequently, it has 
been employed for haploidentical transplant demonstrating powerful 
leukemia control with low relapse rates, thus translating into satisfac- 
tory outcome.
15–19
 Nevertheless, data reporting the use of TBF pre 
allo-SCT from matched siblings (MSD) and unrelated donors (UD) are 
rather limited and mostly preliminary.
20,21
 In a recent EBMT study
22
 
we observed impressive low relapse rate following TBF in a large 
cohort of AML patients transplanted from MSD or UD. Given the con- 
stantly increasing number of allo-SCT performed with the TBF 
 
protocol all over Europe, and the lack of a comparison of this regimen 
with standard myeloablative protocols, we designed the current study 
to compare outcome of TBF vs. BuCy before allo-SCT from MSD or 




2 | METHODS  
 
2.1 | Study design and data collection 
This is a registry-based retrospective study. Data were provided and 
the study design was approved by the acute leukemia working party 
(ALWP) of the European society for blood and marrow transplantation 
(EBMT), in accordance with the EBMT guidelines for retrospective 
studies. EBMT is a voluntary working group of more than 500 trans- 
plant centers which are required to report all consecutive stem cell 
transplantations and follow-up once a year. Audits are routinely per- 
formed to determine the accuracy of the data. Since 1990, patients 
have been able to provide informed consent that authorizes the use 
of their transplant information for research purposes. The ALWP of 
the EBMT granted ethical approval for this study. 
We included in the analysis patients with AML aged between 
18 and 50 years, who had received either TBF or BuCy as conditioning 
regimen for MSD or UD SCT in CR between January 2007 and 
December 2015. All unrelated donors were HLA-matched (10/10) or 
mismatched at one HLA locus (9/10) by high resolution typing. Patients 
who received conditioning regimens including oral busulfan, T-depleted 
grafts, or transplant from <9/10 mismatched unrelated donor were 
excluded. All patients received myeloablative conditioning regimen 
(MAC), defined as intravenous (iv) Busulfan dose ≥ 9.6 mg/kg. 
 
2.2 | End-point definitions and statistical analysis 
Primary end-points were overall survival (OS) and leukemia-free sur- 
vival (LFS). Secondary end-points were relapse incidence (RI), nonre- 
lapse mortality (NRM), graft-vs.-host free, relapse-free survival 
(GRFS), engraftment, incidence and severity of acute (aGVHD) and 
chronic graft-vs.-host disease (cGVHD). The severity of acute GVHD 
was graded on an I-IV scale, while cGVHD was scored as mild, moder- 
ate or severe in accordance with EBMT standards.
23
 LFS was defined 
  
as the interval from transplant to either relapse or death. OS was 
defined as the time between the date of transplant and the date of 
death. GVHD free, relapse free survival (GRFS) was defined as survival 
without the following events: grades 3-4 acute GVHD, severe 
cGVHD, disease relapse, or death from any cause after transplanta- 
tion.
24
 Probabilities of OS, LFS and GRFS were estimated using 
Kaplan-Meier curves. Cumulative incidence functions were used to 
estimate relapse incidence (RI) and nonrelapse mortality (NRM) in a 
competing risks setting. In order to study acute and chronic GVHD, 
we considered death and relapse as competing events. A 1:3 pair 
matched analysis was performed using propensity score matching. 
Matching factors included age at HSCT, disease status, year of trans- 
plant, time from diagnosis to transplant, donor type, CMV serology of 
donor and recipient, stem cell source, GVHD prophylaxis and use of 
ATG. The main patient characteristics were compared using Mann- 
Whitney test for quantitative variables, chi-square test or Fisher exact 
test for categorical variables. Univariate analyses were performed 
using the log-rank test for OS, LFS, and GRFS, the Gray test for cumu- 
lative incidences. Adjusted hazard ratios comparing TBF vs. BuCy 
were calculated using the multivariate Cox proportional-hazard model. 
Proportional-hazard assumption was tested using Schoenfeld resid- 
uals. We performed subgroup analysis in patients receiving transplant 
in CR1 and in TBF patients who received busulfan 9.6 mg/kg when 
compared with BuCy patients receiving busulfan 12.8 mg/kg. All tests 
were two sided. The type I error rate was fixed at .05 for statistical 
testing. 95% Confidence Intervals was provided for time to event out- 
comes and hazard ratio. Statistical analyses were performed with 
SPSS 19 (SPSS, Chicago, IL), and R 2.13.2 (R Development Core Team, 
Vienna, Austria) software packages. 
 
 
3 | RESULTS  
 
3.1 | Patient, disease and transplant characteristics 
Two thousand five hundred and twenty-three patients fulfilled the 
inclusion criteria for the present analysis; among them, 153 received 
TBF and 2370 BuCy, respectively. Among all patients, 2044 under- 
went allo-SCT in first complete remission (CR1) while 479 in subse- 
quent CR. One thousand five hundred and fifty-six patients (62%) 
were transplanted from MSD, 722 (29%) from 10/10 UD and 
245 (9%) from 9/10 UD, respectively.  Median follow-up was 
22 months. Cytogenetic data were available in 45% of patients; 
among them, 22% had favorable, 61% intermediate, and 17% adverse 
cytogenetics. 
The TBF group included significantly older patients compared with 
the BuCy cohort (38 vs. 37 years, P = .024). The median year of trans- 
plant was 2014 (range 2008-2015) for TBF and 2011 (range 
2007-2015) for BuCy, respectively (P < 10−4). Patients undergoing TBF 
were more likely to have received a UD transplant when compared 
with BuCy (52% vs. 37%, P < 10−4). Stem cell source in the TBF group 
was more frequently BM (35% vs. 25%, P = .02) and GVHD prophylaxis 
CSA + MMF (13% vs. 5%, P < 10−4) when compared with BuCy; fur- 
ther, CMV serostatus of donor and patient differed between the two 
cohorts (P < 10−4). Cytogenetic risk, Karnofsky performance score, the 
 
proportion of patients who received antithymocyte globulin (ATG) and 
donor/patient gender match did not differ between the groups. Among 
the TBF cohort, 64 patients (66%) received busulfan 9.6 mg/kg, while 
33 (34%) received 12.8 mg/kg. Within the BuCy cohort, 121 patients 
(10%) received busulfan 9.6 mg/kg and 1157 (90%) 12.8 mg/kg. Patient 
characteristics are detailed in Table 1. To reduce inherent bias of a non- 
randomized comparison between patients receiving the two different 
regimens, a 1:3 Propensity Score pair-matched analysis was performed, 
as discussed in the methods section. One hundred and forty-six 
patients receiving TBF were matched with 438 patients receiving BuCy; 
the characteristics of the pair-matched populations are detailed in Sup- 
porting Information Table S1. 
 
3.2 | Engraftment, nonrelapse mortality and graft- 
vs.-host disease 
Engraftment rate was 100% and 99% following allo-SCT with TBF 
and BuCy, respectively (P = .4). By univariate analysis, nonrelapse 
mortality was similar between the two cohorts, being 10% and 9% at 
1 year, 22% and 13% at 5 years post allo-SCT with TBF and BuCy, 
respectively (P = .4, Figure 1). Leading causes of NRM in the global 
population were GVHD and infectious complications; the complete 
list of causes of death and their relative incidence are detailed in Table 
S2 (Supporting Information). 
The incidence of grade II-IV acute graft-vs-host disease (aGVHD) 
was similar between the two groups, being 29% and 23% in TBF and 
BuCy, respectively (P = .2). However, when restricting the analysis to 
the incidence of grade III-IV aGVHD, higher rates were observed fol- 
lowing TBF (15%) when compared with the BuCy regimen (8%, 
P = .04). By univariate analysis, the cumulative incidence of cGVHD 
was similar in the two groups, being 36% and 43% at 5 years for TBF 
and BuCy, respectively (P = .7). Similarly, no significant difference was 
observed in the incidence of severe cGVHD, being 16% in the TBF and 
22% in the BuCy group, respectively (P = .7). Multivariate analysis con- 
firmed a trend towards higher risk of grade III-IV aGVHD after TBF 
when compared with BuCy (HR 1.8, CI 1-3.2, P = .06). In contrast, a 
lower risk of cGVHD (HR 0.7, CI 0.5-0.99, P = .04) and a trend towards 
inferior risk of severe cGVHD (HR 0.6, CI 0.3-1.1, P = .1) was observed 
with the TBF regimen when compared with the BuCy protocol. 
 
3.3 | Relapse, leukemia-free survival and overall 
survival 
By univariate analysis, relapse incidence was not statistically different 
between the two conditioning regimens, being 17% and 21% at 1 year, 
25% and 27% at 5 years for TBF and BuCy, respectively (P = .3, 
Figure 1). However, when adjusting for covariates in Cox regression 
analysis, TBF was associated with significantly lower relapse risk when 
compared with BuCy (HR 0.6, CI 0.4-0.9, P = .02). Leukemia-free sur- 
vival was not statistically different between the two groups, being 73% 
and 70% at 1 year, 53 and 50% at 5 years for TBF and BuCy, respec- 
tively (P = .6). Multivariate analysis confirmed those results (Table 2). 
Overall survival did not differ as well; it was 80% and 79% at 1 year 
and 54% and 59% at 5 years for TBF and BuCy, respectively (P = .9, 
Figure 1). These results were confirmed by multivariate analysis. 
  
TABLE 1 Patient, disease and transplant characteristics  
 Overall BuCy TBF P 
Number 2523 2370 153 
 
Follow-up for survivors (months), median (min-max) 21.8 (1-116.6) 21.7 (1-116.6) 22.4 (1-85.8) .83 
Age of patient at HSCT (years), median (min-max) 37 (18-50) 37 (18–50) 38 (19-50) .024 
Age of patient at HSCT (categorical), n (%)    .077 
18-39 years old 1531 (60.7) 1449 (61.1) 82 (53.6) 
 
40-50 years old 992 (39.3) 921 (38.9) 71 (46.4) 
 
Gender of patient, n (%)    .14 
Male 1306 (51.8) 1236 (52.2) 70 (45.8) 
 
Female 1215 (48.2) 1132 (47.8) 83 (54.2) 
 
Age of patient at diagnosis (in years), median (min-max) 36.5 (14.4-49.6) 36.4 (14.4–49.6) 37.5 (18.3-49.5) .037 
Karnofsky performance at SCT, n (%)    .48 
10-80 298 (12.9) 282 (13.1) 16 (10.7) 
 
90-100 2005 (87.1) 1872 (86.9) 133 (89.3) 
 
Missing 220 216 4 
 
Cytogenetics, n (%)    .36 
Good 250 (9.9) 236 (10.0) 14 (9.2) 
 
Intermediate 696 (27.6) 651 (27.5) 45 (29.4) 
 
Poor 188 (7.5) 182 (7.7) 6 (3.9) 
 
Missing 1389 (55.1) 1301 (54.9) 88 (57.5) 
 
FLT3-ITD, n (%)    .26 
Absent 296 (60.7) 279 (61.5) 17 (50.0) 
 
Present 192 (39.3) 175 (38.5) 17 (50.0) 
 
Missing 2035 1916 119 
 
Disease stage, n (%)    .073 
CR1 2044 (81.0) 1930 (81.4) 114 (74.5) 
 
CR2+ 479 (19) 440 (19) 39 (25) 
 
Year of transplant, median (min-max) 2011.0 (2007.0-2015.0) 2011.0 (2007.0–2015.0) 2014.0 (2008.0-2015.0) <.0001 
Time from diagnosis to SCT (months), median (min-max) 5.4 (0.1-124.2) 5.3 (0.1-124.2) 6.3 (0.3-66.7) .001 
Donor, n (%)    <.0001 
MSD 1556 (61.7) 1483 (62.6) 73 (47.7) 
 
UD 10/10 722 (28.6) 670 (28.3) 52 (34.0) 
 
UD 9/10 245 (9.7) 217 (9.2) 28 (18.3) 
 
Donor/recipient sex mismatch, n (%)    .35 
F-M 2020 (81.0) 1892 (80.8) 128 (84.2) 
 
Other 473 (19.0) 449 (19.2) 24 (15.8) 
 
Missing 30 29 1 
 
Stem cell source, n (%)    .017 
BM 647 (25.6) 594 (25.1) 53 (34.6) 
 
PBSCs 1852 (73.4) 1752 (73.9) 100 (65.4) 
 
CMV donor/recipient, n (%)    <.0001 
−/− 621 (27.3) 605 (28.4) 16 (11.0)  
+/− 211 (9.3) 196 (9.2) 15 (10.3)  
−/+ 399 (17.5) 363 (17.1) 36 (24.7)  
+/+ 1044 (45.9) 965 (45.3) 79 (54.1) 
 
Missing 
    
GVHD prevention, n (%)    <.0001 
CSA + MTX 2046 (82.7) 1928 (83.0) 118 (77.6) 
 
CSA + MMF 133 (5.4) 113 (4.9) 20 (13.2) 
 
CSA 125 (5.1) 113 (4.9) 12 (7.9) 
 
MTX 88 (3.6) 87 (3.7) 1 (0.7) 
 
CSA + MMF + MTX 60 (2.4) 60 (2.6) 0 (0.0) 
 
    
(Continues) 
  
TABLE 1 (Continued)  
 Overall BuCy TBF P 
Other 23 (0.9) 22 (0.9) 1 (0.7) 
 
ATG used, n (%)    .064 
No 1770 (70.2) 1652 (69.7) 118 (77.1) 
 
Yes 753 (29.8) 718 (30.3) 35 (22.9) 
 
Busulfan dose, n (%)     
9.6 mg/kg 185 (13.4) 121 (9.7) 64 (66.2) 
12.8 mg/kg 1190 (86.6) 1157 (90.3) 33 (33.8) 
Other/missing 1148 1092 56 
Data are median (range), n (%), or n/N (%). Some percentages do not add up to 100% because of rounding. Abbreviations: ATG, antithymocyte globulin; 
BM, bone marrow; BuCy, busulfan-cyclophosphamide; CMV, cytomegalovirus; CR1, first complete remission; CR2+, second or subsequent complete remis- 
sion; CSA, cyclosporine; FLT3-ITD, fms-like tyrosine kinase-3 internal tandem duplication; GVHD, graft vs. host disease; MMF, mofetil mycophenolate; 
MSD, matched sibling donor; MTX, methotrexate; PBSCs, peripheral blood stem cells; SCT, stem cell transplant; UD, unrelated donor; TBF, 
thiotepa-busulfan-fludarabine. 
 
The composite endpoint GRFS did not differ between the two 
study cohorts being 63% and 56% at 1 year, 48% and 40% at 5 years 
for TBF and BuCy, respectively (P = .5). 
When examining separately patients receiving allo-SCT from 
MSD or UD, no significant difference was observed between the TBF 
and BuCy regimens regarding transplant outcome. 
 
3.4 | Subgroup analysis 
We conducted a subgroup analysis in patients receiving transplant in 
CR1. In this subpopulation, TBF was associated with significantly 
lower relapse risk when compared with BuCy (HR 0.4, CI 0.2-0.7, 
P = .02), while NRM was not statistically different (TBF vs. BuCy: HR 
1.6, CI 0.9-2.8, P = .15). Those results led to a trend for better LFS in 
favor of TBF in this population (HR 0.7, CI 0.5-1.1, P = .10), while OS 
did not differ between the two groups (TBF vs. BuCy: HR 0.9, CI 
0.6-1.4, P = .7, Figure 2). In this subgroup of patients, the risk of 
developing aGVHD was not statistically different between the two 
regimens (P = .13), while a lower risk of cGVHD was observed follow- 
ing TBF when compared with BuCy (HR 0.7, CI 0.45-1, P = .05), con- 
sistently with the results observed in the global population. Notably, 
GRFS was in favor of TBF with no statistically significant difference 




FIGURE 1 Transplant outcome following TBF vs. BuCy conditioning. RI, relapse incidence; NRM, nonrelapse mortality; LFS, leukemia-free 
survival; OS, overall survival 
  
TABLE 2 Multivariate analysis of transplantation outcome 
 
Conditioning regimen NRM   RI   LFS   OS  
 
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P 








TBF 1.42 (0.84, 2.39) .19 0.61 (0.40, 0.93) .02 0.83 (0.60, 1.15) .27 1.03 (0.73, 1.46) .87 
             
Conditioning regimen aGVHD III-IV cGVHD Severe cGVHD GRFS 
 
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P 








TBF 1.79 (0.99, 3.24) .06 0.70 (0.49, 0.99) .04 0.61 (0.34, 1.10) .10 0.79 (0.59, 1.06) .12 
Abbreviations: BuCy, busulfan-cyclophosphamide; cGVHD, chronic graft-vs.-host disease; GRFS, graft-vs.-host-free, relapse-free survival; LFS, 
leukemia-free survival; NRM, nonrelapse mortality; OS, overall survival; TBF, thiotepa-busulfan-fludarabine. 
 
Finally, we conducted a subgroup analysis comparing TBF 
patients who received busulfan 9.6 mg/kg to BuCy patients receiving 
busulfan 12.8 mg/kg, according to standard regimen schedules. We 
observed similar RI and NRM after the two regimens with the selected 
doses of busulfan, leading to similar LFS (BuCy vs. TBF: HR 1.3, CI 
0.8-2.3, P = .28) and OS (BuCy vs. TBF: HR 1.1, CI 0.6-1.9, P = .8). 
Interestingly, with the reduced dose of busulfan in the TBF regimen, 
incidence of aGVHD was decreased (cumulative incidence of aGVHD 
III-IV at 100 day: 10%), this rate being not statistically different when 
compared with BuCy (BuCy vs. TBF: HR 0.8, CI 0.3-2.1, P = .7). In 
contrast, similarly to what observed in the global population, incidence 
of cGVHD was inferior following TBF conditioning when compared 
with BuCy protocol (BuCy vs. TBF: HR 2.4, CI 1.3-4.4, P = .006). This 
result led to a trend for better GRFS for TBF when compared with 
BuCy in this subgroup of patients (BuCy vs. TBF: HR 1.5, CI 
0.96-1.2.5, P = .07). 
 
 
4 | DISCUSSION  
 
The optimal conditioning regimen for young, fit patients with AML is a 
matter of debate. We hypothesized that the combination of thiotepa, 
busulfan and fludarabine, which is being increasingly employed all 





FIGURE 2 Transplant outcome following TBF vs. BuCy conditioning in patients in first complete remission. RI, relapse incidence; NRM, 
nonrelapse mortality; LFS, leukemia-free survival; OS, overall survival 
 to BuCy, capable of providing effective leukemia control in allo-SCT 
from MSD or UD for young patients with AML. In fact, in the present 
study, we observed significantly lower relapse after the TBF regimen 
when compared with BuCy, which translated in a trend for better 
leukemia-free survival in patients transplanted in first remission. Nota- 
bly, the incidence of relapse was as low as 25% at 5 years following 
TBF. Moreover, when selecting patients in CR1, relapse was 10% at 
1 year and less than 18% at 5 years. When compared with BuCy, the 
hazard ratio for relapse risk was below 0.5, with high statistical signifi- 
cance. Such results compare favorably with historical data reporting 
outcome after standard myeloablative regimens; indeed in an EBMT 
study conducted on a similar population, relapse rate after CyTBI 
exceeded 20% at 2 years.
25
 
In fact, despite optimization of transplant procedures, leukemia 
recurrence remains the main cause of transplant failure. Further, 
recent evidence emerging from randomized trials
8,9
 demonstrated 
that mitigating the intensity of the conditioning might not be the right 
strategy for young, fit AML patients. In accordance to these data, the 
recent GITMO trial comparing a “reduced toxicity” regimen (BuFlu) 
with standard BuCy protocol enrolled patients above the age of 40;
26
 
in this study, the long-term RI did not differ between the two arms 
and exceeded 35% in the BuCy cohort. In a recent EBMT survey
25
 the 
incidence of relapse was higher following BuCy when compared with 
CyTBI. Our result of low relapse rate following TBF is consistent with 
the previous evidence. In the first study reporting this protocol as the 
preparatory regimen for cord blood transplant,
13
 relapse incidence 
accounted for 18% at 5 years. Subsequently, this conditioning was 
employed in haplo-SCT by two different Italian groups. In the study 
led by the centres of Rome and Pescara
18
 the use of TBF was the only 
factor predicting a lower risk of relapse in multivariate analysis. Simi- 
larly, Bacigalupo et al.
16
 observed a cumulative incidence of relapse 
related death of 11% for patients transplanted in CR1 following the 
TBF protocol; this result was recently confirmed by a multicenter 
trial.
27
 In a recent EBMT study,
22
 we reported the outcome of TBF 
regimen in a large cohort of AML patients transplanted from MSD or 
UD, demonstrating impressive low relapse (14% at 2 years) following 
this protocol. The latter finding encouraged us to challenge TBF with 
a standard myeloablative regimen as BuCy, laying the groundwork for 
the present study. It might be hypothesized that the joint power of 
two alkylators holding a potent anti-leukemic activity and a significant 
penetration to sanctuary sites result in effective control of residual 
disease and prevention of leukemia recurrence. 
Importantly, the reduced relapse following TBF translated in a 
tendency towards better leukemia-free survival in the subgroup of 
patients transplanted in CR1, this advantage being not evident in the 
global population. Similarly, no difference was seen in overall survival 
between the two regimens. Indeed, it should be highlighted that non- 
relapse mortality following TBF exceeded 20% at 5 years; this rate 
was not statistically different when compared with BuCy. This result 
compares favorably with mortality rates reported in previous studies 
employing TBF in cord blood (Sanz et al.
13
 5-year NRM: 44%), and 
haplo-SCT (Arcese et al.
19
 cumulative incidence of NRM: 32%). In a 
recent preliminary report by Sora et al.
28
 the authors observed 
impressively low relapse and nonrelapse mortality rates. 
 
The leading causes of death were represented by disease recur- 
rence, GVHD, and infection. We observed a tendency towards a 
higher incidence of grades III-IV aGVHD following TBF when com- 
pared with BuCy. It might be hypothesized that thiotepa in combina- 
tion with high dose busulfan is responsible for substantial injury to the 
gut mucosa, thus leading to the release of pro-inflammatory cytokines 
triggering aGVHD. In fact, a significant proportion of TBF patients 
included in this analysis had received busulfan 12.8 mg/kg which, in 
combination with thiotepa, appears to be excessively toxic, as showed 
by previous evidence.
22
 In fact, when the analysis on TBF was 
restricted to patients receiving the “standard” schedule with busufan 
9.6 mg/kg, the incidence of severe aGVHD was reduced, and resulted 
similar to the one observed after BuCy. Based on these and previous 
data,
22
 the combination of thiotepa with busulfan 12.8 mg/kg should 
be avoided, and the “standard” busulfan 9.6 mg/kg schedule should 
be preferred instead. 
Interestingly, we observed lower incidence of cGVHD after TBF 
when compared with BuCy. This translated into a trend for better 
GRFS following TBF, which was more evident in the subgroup of 
patients receiving TBF with busulfan 9.6 mg/kg. 
It is important to recognize the limitations of the present study. 
The retrospective design did not allow to study the reason for patient 
allocation to a specific regimen, which could have influenced the anal- 
ysis. Further, some of the patient characteristics differed among the 
two cohorts; however, this limitation was addressed by performing a 
propensity score pair-matched analysis based on the most relevant 
patient, disease and transplant characteristics. Finally, about 50% of 
the patients lacked informative data about cytogenetic risk. However 
when we restricted the analysis to patients with available cytogenet- 
ics, results were comparable to the global population (data not shown), 
suggesting a homogeneous distribution of disease risk among the 
study cohorts. Nevertheless, the retrospective nature of the study 
does not allow to firmly exclude the theoretic possibility that imbal- 
ances between the groups could have influenced at least in part 
outcome. 
In conclusion, our results suggest that TBF represents a valid 
myeloablative regimen, able to provide significantly lower relapse and 
similar survival when compared with BuCy. Patients in first remission 
appear to gain the most from this protocol, as in this subgroup a ten- 
dency for better leukemia-free survival was observed when compared 
with BuCy. Finally, the dose of busulfan within the TBF regimen 
should not exceed 9.6 mg/kg, as this schedule seems able to retain 
strong anti-leukemic effect in combination with acceptable nonrelapse 
mortality. Prospective, randomized trials are warranted to validate our 
results, aiming at identifying the best myeloablative conditioning regi- 
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